- The fearless CEO is back! After missing one investor presentation, he tries to pack double your money's worth of enthusiasm into this presentation. Poor sound quality and he didn't manage to leave time for questions.
- Click here for more info on SPPI and click here for complete biotech webcast listings and links to my notes.
- Keep reading for my notes:
- Company founded in 2002 and seeks a diversified late stage oncology portfolio
- two NDAs expected to be filed in next 12 months
- We have little operating cash requirement. Cash flow positive right now
- 3 consecutive quarters of profitability
- Fusilev does $100m sales in Japan by Takeda, $80m EU sales by Pfizer PFE and Sanofi SNY
- Zevalin chart shows projection for y/y growth in sales 2011, but 1h sales are <50% of 2010 level (no comment on how this would be achieved, since any benefit from November PDUFA date for bioscan removal wouldn't impact 2011 sales numbers)
- Zevalin is rated NCCN category 1, which requires unquestionable efficacy, and must be reimbursed (CMS guidelines)
- When Zevalin was launched by Biogen BIIB in 2002, doctors lost money on the drug
- We are starting studies with Zevalin in more agressive lymphoma [no details or timetable still]
- November 20th PDUFA for bioscan removal. I think this approval would cause different course of revenue generation for the drug
- belinostat we will complete pivotal PTCL trial any day now (huh? doesnt match prior guidance..maybe meant to say enrollment complete?) and file NDA next year
- Belinostat: we have data in over 700 patients now
- apaziquone - acquired rights from EORTC (European equivalent of NCI) for $100k, no future milestones/royalties owed
- no time for q&a